# Mesoblast Ltd: overview MESO · Nasdaq · CIK 1345099 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/meso.md) · [Financials](/companies/meso/financials.md) · [Filings](/companies/meso/filings.md) · [Insiders](/companies/meso/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-06-30) | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [7.4](/filings/0001345099-23-000059.md) | [10.2](/filings/0001345099-24-000063.md) | [7.5](/filings/0001345099-25-000067.md) | [5.9](/filings/0001345099-25-000067.md) | [17.2](/filings/0001345099-25-000067.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | [(1329.2%)](/filings/0001345099-23-000059.md) | [(894.6%)](/filings/0001345099-24-000063.md) | [(1091.7%)](/filings/0001345099-25-000067.md) | [(1490.3%)](/filings/0001345099-25-000067.md) | [(593.9%)](/filings/0001345099-25-000067.md) | | Diluted EPS | $ per share | [(0.16)](/filings/0001345099-23-000059.md) | [(0.13)](/filings/0001345099-24-000063.md) | [(0.11)](/filings/0001345099-25-000067.md) | [(0.09)](/filings/0001345099-25-000067.md) | [(0.08)](/filings/0001345099-25-000067.md) | | Free cash flow | $m | not reported | not reported | [(63.5)](/filings/0001345099-25-000067.md) | [(48.7)](/filings/0001345099-25-000067.md) | [(50.6)](/filings/0001345099-25-000067.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/meso/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $16.1m | 1,189,800 | Call | Added +451,400 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $9.9m | 734,700 | Call | Added +316,400 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $9.7m | 718,608 | | Added +204,177 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $9.0m | 664,280 | | Added +33,425 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $6.2m | 457,744 | | Added +71,272 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $5.4m | 398,000 | Call | Added +170,600 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $5.4m | 395,612 | | Reduced −1,603 | | [BNP PARIBAS ASSET MANAGEMENT Holding S.A.](/funds/1520354.md) | 2026-06-30 | $3.5m | 259,700 | | New +259,700 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $2.7m | 200,053 | | Added +67,480 | | [Arax Advisory Partners](/funds/1586767.md) | 2026-06-30 | $2.3m | 168,022 | | Added +143,597 | ## Recent filings [All 567 filings](/companies/meso/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 06:57 ET | [6-K](/filings/0001345099-26-000093.md) | Report of a foreign private issuer, period 2026-10-29 | 0001345099-26-000093 | | 2026-10-16 | 21:29 ET | [6-K](/filings/0001345099-26-000091.md) | Report of a foreign private issuer, period 2026-10-16 | 0001345099-26-000091 | | 2026-10-15 | 07:37 ET | [6-K](/filings/0001345099-26-000089.md) | Report of a foreign private issuer, period 2026-10-14 | 0001345099-26-000089 | | 2026-10-13 | 06:27 ET | [6-K](/filings/0001345099-26-000087.md) | Report of a foreign private issuer, period 2026-10-13 | 0001345099-26-000087 | | 2026-09-24 | 21:14 ET | [6-K](/filings/0001345099-26-000085.md) | Report of a foreign private issuer, period 2026-09-24 | 0001345099-26-000085 | | 2026-08-27 | 07:09 ET | [6-K](/filings/0001345099-26-000083.md) | Report of a foreign private issuer, period 2026-08-27 | 0001345099-26-000083 | | 2026-08-27 | 06:08 ET | [20-F](/filings/0001345099-26-000081.md) | Annual report of a foreign private issuer, period 2026-06-30 | 0001345099-26-000081 | | 2026-08-25 | 20:43 ET | [6-K](/filings/0001345099-26-000078.md) | Report of a foreign private issuer, period 2026-08-25 | 0001345099-26-000078 | | 2026-08-24 | 09:36 ET | [6-K](/filings/0001345099-26-000076.md) | Report of a foreign private issuer, period 2026-08-24 | 0001345099-26-000076 | | 2026-08-18 | 17:34 ET | [6-K](/filings/0001345099-26-000074.md) | Report of a foreign private issuer, period 2026-08-17 | 0001345099-26-000074 | ## Latest annual report [Form 20-F for the fiscal year ended Jun 30, 2026](/filings/0001345099-26-000081.md), filed Aug 27, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1345099 - Tickers: MESO, MEOBF - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: C3 - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 06:58 ET. No prices; not investment advice.